Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond

BackgroundMetastatic renal cell carcinoma (mRCC) represents a significant challenge due to variable patient outcomes despite advancements in treatment. Nivolumab, a programmed death-1 (PD-1) inhibitor, has demonstrated efficacy as a second-line or later therapy following progression on tyrosine kina...

Повний опис

Бібліографічні деталі

Автори:	Bülent Erdoğan, İvo Gökmen, Cagnur Elpen Kodaz, Ahmet Küçükarda, Didem Divriklioğlu, İsmail Bayrakçı, İlhan Hacıbekiroğlu, Esra Özen Engin, Muhammet Bekir Hacıoğlu, Erkan Özcan, Gökhan Öztürk, Hilmi Kodaz
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2025-10-01
Серія:	Frontiers in Oncology
Предмети:	metastatic renal cell carcinoma GRIm score nivolumab second-line therapy prognostic biomarker
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1657053/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!